{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:00:09Z","timestamp":1780560009056,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100022748","name":"Universidade Fernando Pessoa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Heparanase uniquely cleaves heparan sulfate, the main component of the outer layer of endothelial cell plasma membranes, promoting tumour invasion and dissemination. However, it can also enhance tumour immune surveillance and clearance. heparanase\u2019s versatility extends to pro-thrombotic properties, such as the promotion of tissue factor release. Interestingly, elevated heparanase levels have been found in ovarian cancer (OC), which has a notably high incidence of venous thrombosis. Previously, single-nucleotide polymorphisms (SNPs) of\n                      <jats:italic>HPSE<\/jats:italic>\n                      were shown to modulate mRNA and protein levels, possibly predicting disease outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      Given the potential role of heparanase in OC, the implications of three SNPs - rs11099592, rs4364254 and rs4693608 - were investigated in OC patients. In the discovery cohort, rs11099592 TT genotype and rs4364254 C allele carriers showed lower survival time than their counterparts (log-rank test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001, respectively). Validation cohort analysis confirmed the worse prognosis associated with the rs11099592 T allele and the rs4364254 C allele in non-serous (log-rank test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) and platinum-resistant (log-rank test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044) OC patients, respectively. The rs4364254 C allele was associated with reduced\n                      <jats:italic>HPSE<\/jats:italic>\n                      expression in peripheral blood components (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), suggesting a protective role for HPSE in OC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>HPSE<\/jats:italic>\n                      rs11099592 and rs4364254 showed prognostic value, with T and C allele carriers, respectively, displaying worse clinical outcomes. These results indicate that heparanase could enable a tumour microenvironment shift towards a less aggressive cancer behaviour, facilitating leukocyte migration and anti-tumour responses. Further research should explore the dual mechanisms of this protein to improve OC management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-11891-y","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:34:08Z","timestamp":1777966448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts"],"prefix":"10.1007","volume":"53","author":[{"given":"In\u00eas Guerra","family":"de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Savva-Bordalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Rei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Liz-Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"11891_CR1","doi-asserted-by":"publisher","first-page":"1146685","DOI":"10.3389\/fmolb.2023.1146685","volume":"10","author":"YE Liao","year":"2023","unstructured":"Liao YE, Liu J, Arnold K (2023) Heparan sulfates and heparan sulfate binding proteins in sepsis. Front Mol Biosci 10:1146685","journal-title":"Front Mol Biosci"},{"issue":"3","key":"11891_CR2","first-page":"443","volume":"17","author":"XM van Wijk","year":"2014","unstructured":"van Wijk XM, van Kuppevelt TH (2014) Heparan sulfate in angiogenesis: a target for therapy. Angiogenesis 17(3):443\u2013462","journal-title":"Angiogenesis"},{"issue":"20","key":"11891_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2174\/138161207781039742","volume":"13","author":"I Vlodavsky","year":"2007","unstructured":"Vlodavsky I et al (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13(20):2057\u20132073","journal-title":"Curr Pharm Des"},{"issue":"8 Suppl 1","key":"11891_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/IJG.0000000000000108","volume":"23","author":"B Yue","year":"2014","unstructured":"Yue B (2014) Biology of the extracellular matrix: an overview. J Glaucoma 23(8 Suppl 1):S20\u2013S23","journal-title":"J Glaucoma"},{"key":"11891_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drup.2016.10.001","volume":"29","author":"I Vlodavsky","year":"2016","unstructured":"Vlodavsky I et al (2016) Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat 29:54\u201375","journal-title":"Drug Resist Updat"},{"issue":"5","key":"11891_CR6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jcp.30995","volume":"238","author":"Y Yang","year":"2023","unstructured":"Yang Y et al (2023) Potential roles of heparanase in cancer therapy: Current trends and future direction. J Cell Physiol 238(5):896\u2013917","journal-title":"J Cell Physiol"},{"key":"11891_CR7","doi-asserted-by":"publisher","first-page":"926353","DOI":"10.3389\/fchem.2022.926353","volume":"10","author":"F Yuan","year":"2022","unstructured":"Yuan F et al (2022) Heparanase in cancer progression: Structure, substrate recognition and therapeutic potential. Front Chem 10:926353","journal-title":"Front Chem"},{"key":"11891_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens15020186","author":"S Akinsiku","year":"2026","unstructured":"Akinsiku S, Shukla D (2026) Molecular pathways driving corneal neovascularization in Herpes Simplex Keratitis. Pathogens 15(2), 186 https:\/\/doi.org\/10.3390\/pathogens15020186","journal-title":"Pathogens"},{"issue":"2","key":"11891_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ygyno.2006.08.045","volume":"104","author":"B Davidson","year":"2007","unstructured":"Davidson B et al (2007) Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol 104(2):311\u2013319","journal-title":"Gynecol Oncol"},{"issue":"5","key":"11891_CR10","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3892\/or.2013.2701","volume":"30","author":"W Zhang","year":"2013","unstructured":"Zhang W et al (2013) Overexpression of heparanase in ovarian cancer and its clinical significance. Oncol Rep 30(5):2279\u20132287","journal-title":"Oncol Rep"},{"key":"11891_CR11","doi-asserted-by":"publisher","first-page":"153303382412812","DOI":"10.1177\/15330338241281285","volume":"23","author":"W Kong","year":"2024","unstructured":"Kong W et al (2024) Analysis of Expression Pattern and Prognostic Value of the Heparanase in Breast Cancer Through CD274\/CTLA-4 Immune Checkpoint Proteins. Technol Cancer Res Treat 23:15330338241281285","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"11891_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5041\/RMMJ.10349","volume":"9","author":"Y Nadir","year":"2018","unstructured":"Nadir Y, Brenner B (2018) Cancer and thrombosis-new insights. Rambam Maimonides Med J 9(4):1\u20137","journal-title":"Rambam Maimonides Med J"},{"issue":"10","key":"11891_CR13","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"5","key":"11891_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12185-024-03735-x","volume":"119","author":"K Tatsumi","year":"2024","unstructured":"Tatsumi K (2024) The pathogenesis of cancer-associated thrombosis. Int J Hematol 119(5):495\u2013504","journal-title":"Int J Hematol"},{"issue":"1","key":"11891_CR15","doi-asserted-by":"publisher","first-page":"2437917","DOI":"10.1080\/2162402X.2024.2437917","volume":"14","author":"S Liborio-Ramos","year":"2025","unstructured":"Liborio-Ramos S et al (2025) An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells. Oncoimmunology 14(1):2437917","journal-title":"Oncoimmunology"},{"issue":"5","key":"11891_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I et al (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21(5):524\u2013529","journal-title":"Nat Med"},{"issue":"10","key":"11891_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A et al (2023) Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34(10):833\u2013848","journal-title":"Ann Oncol"},{"issue":"12","key":"11891_CR18","doi-asserted-by":"publisher","first-page":"10179","DOI":"10.3390\/curroncol30120741","volume":"30","author":"R Sowamber","year":"2023","unstructured":"Sowamber R et al (2023) Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs. Curr Oncol 30(12):10179\u201310194","journal-title":"Curr Oncol"},{"issue":"1","key":"11891_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/curroncol31010007","volume":"31","author":"S Moufarrij","year":"2023","unstructured":"Moufarrij S, O\u2019Cearbhaill RE (2023) Novel therapeutics in ovarian cancer: Expanding the toolbox. Curr Oncol 31(1):97\u2013114","journal-title":"Curr Oncol"},{"key":"11891_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031845","author":"V Tavares","year":"2024","unstructured":"Tavares V et al (2024) Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. Int J Mol Sci 25, 1845 https:\/\/doi.org\/10.3390\/ijms25031845","journal-title":"Int J Mol Sci"},{"issue":"5","key":"11891_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5694\/mja2.52227","volume":"220","author":"M Sideris","year":"2024","unstructured":"Sideris M, Menon U, Manchanda R (2024) Screening and prevention of ovarian cancer. Med J Aust 220(5):264\u2013274","journal-title":"Med J Aust"},{"key":"11891_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010140","author":"IS Marques","year":"2023","unstructured":"Marques IS et al (2023) Long non-coding RNAs: bridging cancer-associated thrombosis and clinical outcome of ovarian cancer patients. Int J Mol Sci 25, 140 https:\/\/doi.org\/10.3390\/ijms25010140","journal-title":"Int J Mol Sci"},{"key":"11891_CR23","doi-asserted-by":"publisher","first-page":"122178","DOI":"10.1016\/j.lfs.2023.122178","volume":"333","author":"ND McKenzie","year":"2023","unstructured":"McKenzie ND et al (2023) Prognostic features of the tumor microenvironment in high-grade serous ovarian cancer and dietary immunomodulation. Life Sci 333:122178","journal-title":"Life Sci"},{"issue":"2","key":"11891_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1189\/jlb.1208735","volume":"86","author":"O Ostrovsky","year":"2009","unstructured":"Ostrovsky O et al (2009) Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. J Leukoc Biol 86(2):445\u2013455","journal-title":"J Leukoc Biol"},{"key":"11891_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS et al (2021) Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet 155:61\u201385","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"11891_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"9","key":"11891_CR27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3324\/haematol.2016.147405","volume":"101","author":"OV Gran","year":"2016","unstructured":"Gran OV et al (2016) Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica 101(9):1046","journal-title":"Haematologica"},{"key":"11891_CR28","doi-asserted-by":"publisher","first-page":"149378","DOI":"10.1016\/j.gene.2025.149378","volume":"950","author":"V Tavares","year":"2025","unstructured":"Tavares V et al (2025) Heritable Genetic Variability in Ovarian Tumours: Exploring Venous Thromboembolism Susceptibility and Cancer Prognosis in a Hospital-Based Study. Gene 950:149378","journal-title":"Gene"},{"key":"11891_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-030-34521-1_8","volume":"1221","author":"O Ostrovsky","year":"2020","unstructured":"Ostrovsky O, Vlodavsky I, Nagler A (2020) Mechanism of HPSE gene SNPs function: from normal processes to inflammation, cancerogenesis and tumor progression. Adv Exp Med Biol 1221:231\u2013249","journal-title":"Adv Exp Med Biol"},{"key":"11891_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/life14121630","author":"IG de Melo","year":"2024","unstructured":"de Melo IG et al (2024) Endothelial dysfunction markers in ovarian cancer: VTE risk and tumour prognostic outcomes. Life Basel 14, 1630 https:\/\/doi.org\/10.3390\/life14121630","journal-title":"Life Basel"},{"issue":"13","key":"11891_CR31","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3390\/cancers16132356","volume":"16","author":"V Tavares","year":"2024","unstructured":"Tavares V et al (2024) Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour. Cancers 16(13):2356","journal-title":"Cancers"},{"issue":"1","key":"11891_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L et al (2024) Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer 23(1):66","journal-title":"Mol Cancer"},{"issue":"2","key":"11891_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81\u201394","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"11891_CR34","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.3390\/cimb46050292","volume":"46","author":"IG de Melo","year":"2024","unstructured":"de Melo IG et al (2024) Contribution of Endothelial Dysfunction to Cancer Susceptibility and Progression: A Comprehensive Narrative Review on the Genetic Risk Component. Curr Issues Mol Biol 46(5):4845\u20134873","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"11891_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12967-020-02624-1","volume":"18","author":"KM Jayatilleke","year":"2020","unstructured":"Jayatilleke KM, Hulett MD (2020) Heparanase and the hallmarks of cancer. J Transl Med 18(1):453","journal-title":"J Transl Med"},{"key":"11891_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-34521-1_1","volume":"1221","author":"I Vlodavsky","year":"2020","unstructured":"Vlodavsky I, Ilan N, Sanderson RD (2020) Forty years of basic and translational heparanase research. Adv Exp Med Biol 1221:3\u201359","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"11891_CR37","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1002\/mgg3.1257","volume":"8","author":"H Cao","year":"2020","unstructured":"Cao H et al (2020) Correlation between heparanase gene polymorphism and susceptibility to endometrial cancer. Mol Genet Genomic Med 8(10):e1257","journal-title":"Mol Genet Genomic Med"},{"issue":"11","key":"11891_CR38","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/sj.leu.2404821","volume":"21","author":"O Ostrovsky","year":"2007","unstructured":"Ostrovsky O et al (2007) Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21(11):2296\u20132303","journal-title":"Leukemia"},{"key":"11891_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060913","author":"O Ostrovsky","year":"2023","unstructured":"Ostrovsky O et al (2023) Effect of HPSE and HPSE2 SNPs on the risk of developing primary paraskeletal multiple myeloma. Cells 12, 913 https:\/\/doi.org\/10.3390\/cells12060913","journal-title":"Cells"},{"issue":"1","key":"11891_CR40","first-page":"1","volume":"5","author":"U Yetkin","year":"2004","unstructured":"Yetkin U, Karabay O, Onol H (2004) Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases. Curr Control Trials Cardiovasc Med 5(1):1","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"1","key":"11891_CR41","doi-asserted-by":"publisher","first-page":"e30277","DOI":"10.1371\/journal.pone.0030277","volume":"7","author":"AL Li","year":"2012","unstructured":"Li AL et al (2012) Polymorphisms and a haplotype in heparanase gene associations with the progression and prognosis of gastric cancer in a northern Chinese population. PLoS ONE 7(1):e30277","journal-title":"PLoS ONE"},{"key":"11891_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.matbio.2016.03.006","volume":"55","author":"VC Ramani","year":"2016","unstructured":"Ramani VC et al (2016) Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol 55:22\u201334","journal-title":"Matrix Biol"},{"issue":"Suppl 2","key":"11891_CR43","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/S0049-3848(07)70139-1","volume":"120","author":"I Vlodavsky","year":"2007","unstructured":"Vlodavsky I et al (2007) Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 120(Suppl 2):S112\u2013S120","journal-title":"Thromb Res"},{"key":"11891_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fonc.2019.00331","volume":"9","author":"AJ Mayfosh","year":"2019","unstructured":"Mayfosh AJ, Baschuk N, Hulett MD (2019) Leukocyte heparanase: a double-edged sword in tumor progression. Front Oncol 9:331","journal-title":"Front Oncol"},{"issue":"28","key":"11891_CR45","doi-asserted-by":"publisher","first-page":"e2202797","DOI":"10.1002\/advs.202202797","volume":"9","author":"Y Yang","year":"2022","unstructured":"Yang Y et al (2022) Nanomedicine Strategies for Heating Cold Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC. Adv Sci (Weinh) 9(28):e2202797","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"11891_CR46","first-page":"1133","volume":"18","author":"S Ginath","year":"2001","unstructured":"Ginath S et al (2001) Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol 18(6):1133\u20131144","journal-title":"Int J Oncol"},{"issue":"7","key":"11891_CR47","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI92958","volume":"127","author":"EM Putz","year":"2017","unstructured":"Putz EM et al (2017) NK cell heparanase controls tumor invasion and immune surveillance. J Clin Invest 127(7):2777\u20132788","journal-title":"J Clin Invest"}],"updated-by":[{"DOI":"10.1007\/s11033-026-11953-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000}}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11891-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:02:49Z","timestamp":1780556569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11891-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11891"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11891-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8799366\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figures 1\u20135 had been inadvertently swapped. The figures have now been corrected and aligned with their appropriate legends.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11033-026-11953-1","URL":"https:\/\/doi.org\/10.1007\/s11033-026-11953-1","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JLP has received a research Grant from GESCAT-Grupo de Estudos de Cancro e Trombose. This institution had no role in the decision to conduct the study, write and publish this manuscript. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed written consent according to the principles of the Helsinki Declaration was obtained from each patient before their recruitment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}}],"article-number":"713"}}